StreetInsider.com News Articles

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

SUZHOU, China, Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its interim results for the six months ended June 30, 2026 (the "Reporting Period") on August 21, 2026. During the first half of 2026, the Group accelerated commercialization across its core businesses while delivering significant improvements in operational efficiency, profitability and cash generation.

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

Mon, 24 Aug 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical Announces 2025 Annual Results

Thu, 26 Mar 2026 08:00:00 -0400

Peijia Medical receives FDA clearance for DCwire micro guidewire

Wed, 18 Mar 2026 08:00:48 -0400

Peijia Medical (HKG: 9996) announced that its DCwire Micro Guidewire received 510(k) clearance from the U.S. Food and Drug Administration on March 17, 2026, according to a company statement.

The product was developed by Achieva Medical Limited, a subsidiary of the Suzhou, China-based company. This marks the first FDA-cleared product in Peijia Medical's portfolio.

The DCwire Micro Guidewire is designed for neurointerventional procedures. The FDA clearance enables the company to market the device in the United States.

"We are delighted to achieve this important milestone with the FDA clearance of DCwire," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "This accomplishment

Peijia Medical receives FDA clearance for DCwire micro guidewire

Wed, 18 Mar 2026 08:00:48 -0400

Peijia Medical (HKG: 9996) announced that its DCwire Micro Guidewire received 510(k) clearance from the U.S. Food and Drug Administration on March 17, 2026, according to a company statement.

The product was developed by Achieva Medical Limited, a subsidiary of the Suzhou, China-based company. This marks the first FDA-cleared product in Peijia Medical's portfolio.

The DCwire Micro Guidewire is designed for neurointerventional procedures. The FDA clearance enables the company to market the device in the United States.

"We are delighted to achieve this important milestone with the FDA clearance of DCwire," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "This accomplishment

Peijia Medical receives FDA clearance for DCwire micro guidewire

Wed, 18 Mar 2026 08:00:48 -0400

Peijia Medical (HKG: 9996) announced that its DCwire Micro Guidewire received 510(k) clearance from the U.S. Food and Drug Administration on March 17, 2026, according to a company statement.

The product was developed by Achieva Medical Limited, a subsidiary of the Suzhou, China-based company. This marks the first FDA-cleared product in Peijia Medical's portfolio.

The DCwire Micro Guidewire is designed for neurointerventional procedures. The FDA clearance enables the company to market the device in the United States.

"We are delighted to achieve this important milestone with the FDA clearance of DCwire," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "This accomplishment

Peijia Medical receives FDA clearance for DCwire micro guidewire

Wed, 18 Mar 2026 08:00:48 -0400

Peijia Medical (HKG: 9996) announced that its DCwire Micro Guidewire received 510(k) clearance from the U.S. Food and Drug Administration on March 17, 2026, according to a company statement.

The product was developed by Achieva Medical Limited, a subsidiary of the Suzhou, China-based company. This marks the first FDA-cleared product in Peijia Medical's portfolio.

The DCwire Micro Guidewire is designed for neurointerventional procedures. The FDA clearance enables the company to market the device in the United States.

"We are delighted to achieve this important milestone with the FDA clearance of DCwire," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "This accomplishment

DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical's Global Expansion

Wed, 18 Mar 2026 08:00:00 -0400

SUZHOU, China, March 18, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its DCwire^® Micro Guidewire has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") on March 17, 2026. The product was independently designed and developed by Achieva Medical Limited, a subsidiary of the Company.